Navigation Links
Sinobiopharma Announces Second Quarter 2010 Financial Results
Date:1/19/2010

in sales of KuTai (cisatracurium besylate). Increased marketing efforts and adoption by physicians are driving KuTai sales growth. -- Gross margin increased 182% to $1,720,308 (80% of sales) for the three months that ended November 30, 2009, from $610,752 (63% of sales) for the three months that ended November 30, 2008. The improvement in gross margin was attributable to operating leverage; as volume increased, the unit cost of manufacturing KuTai has decreased. The improvement in gross margin was also attributable to an increase in the price of KuTai, which is distributed through a GSP licensed distributor while Sinobiopharma controls marketing, delivery terms and pricing. -- The operating expenses for the three months ended November 30, 2009 were $596,154, representing a 63% decrease as compared to $1,594,819 for the three months that ended November 30, 2008. The drop was primarily attributable to the decrease in stock-based compensation expenses, and to a lesser degree to a decline in expenses from reverse takeover activities in the three months that ended November 30, 2008. -- Research and development expenses increased $189,396 from $33,015 for the three months ended November 30, 2008 to $222,411 for the three months that ended November 30, 2009. The increase was mainly due to the technology consulting expenses related to the new drug YiTai (perindopril), for which Sinobiopharma scaled up for production in November 2009, and expenditures related to the research and development of other new drugs during the three-month period that ended November 30, 2009. -- Other expenses decreased $10,568 from $61,172 for the three months that ended November 30, 2008 to $50,604 for the three months that ended November 30, 2009. This decrease was due to a lowered balance of the shareholder loan,
'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
8. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
9. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
10. Emissary Capital Group Initiates Coverage on Sinobiopharma
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... DUBLIN , May 05, 2015 Research ... announced the addition of the "Clinical Laboratory, ... and Forecast 2015 to 2019 - Global Version" ... technical developments especially in the area of molecular ... dynamic, growing and evolving world market that is ...
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire/ ... today announced that David R. Parkinson , ... (NEA), has been appointed to the board of ... twenty years of experience in oncology clinical development, ... that resulted in global approvals of the cancer ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 Synedgen ... Nguyen, PhD as Regulatory Affairs Manager. , Dr. Nguyen ... an important juncture for the company as it moves ... drug products over the next two years. Dr. Nguyen ... of all the regulatory key documents that must be ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - JSS Medical Research Inc., a ... today that it concluded the acquisition of Max Neeman International (MNI), ... Additional regional offices are located in Ahmedabad, Bangalore ... . Through a US subsidiary, a regional office is located ... expansion is supported by the recent equity investment transaction into JSS ...
Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
... Genzyme,Corporation (Nasdaq: GENZ ) confirmed today that it ... BIVN ) at $5.60 in cash per,outstanding common share ... companies. Genzyme already owns approximately 22 percent of the,outstanding ... 100 percent of its preferred stock that carry a ...
... treatment option for asthma patients not fully controlled on ... ... Calif., Sept. 27 Dey, L.P., an,affiliate of Merck KGaA of ... tablets with its,marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX ). ...
... 27 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on commercializing proprietary product candidates for the ... that data from,preclinical studies of ANX-514 (docetaxel ... of Cancer Research (AACR), National Cancer,Institute (NCI) ...
Cached Biology Technology:Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 3Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 2Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... of information, <a target="_blank" href="http://en.wikipedia.org/wiki/Nucleic_acid_sequence,">DNA sequences come ... identify, proof, and discard compromised molecular data has ... endeavor - one that everyone generating sequence data ... sequences for research purposes. "Many researchers find ...
... D.C. Georgetown Lombardi Comprehensive Cancer Center,s Stephen Byers, ... Cancer Institute to address a "provocative question.", The NCI,s ... 24 questions that, if answered, could lead to significant ... such as why obesity contributes to cancer risk ...
... for Autism Research at The Children,s Hospital of Philadelphia ... to identify early signs of autism spectrum disorders (ASD) ... (NIH) Autism Centers of Excellence (ACE) research program. CHOP ... for autism research, which is distributed across nine ACE ...
Cached Biology News:DNA sequences need quality time too - guidelines for quality control published 2Georgetown Lombardi researcher awarded 'Provocative Question' grant from NCI 2Georgetown Lombardi researcher awarded 'Provocative Question' grant from NCI 3CHOP’s Center for Autism Research receives five-year grant as an NIH Autism Center of Excellence 2
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... SYS203 is a complete, flexible system ... small samples, as is frequently required ... designed around Instechs miniature Clark-style polarographic ... inch in diameter (3.2 mm), it ...
... the family of human cullin genes (CUL-1, -2, -3, ... cdc53 gene. Cullin-3 is proposed to be a part ... with cyclin E and targets it for ubiquitination, which ... an activator of cdk2, which leads the cell to ...
... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
Biology Products: